Call for abstracts
Abstract Submission Period
Abstracts for oral, poster or video presentation
Wednesday, 6th July 2022 – | |
Abstract Submission is now closed. Thank you for your submission. |
Presentation Categories
Please select the most appropriate category for your presentation.
English Session
Presentation style
Oral presentation
Poster Categories
1 | Epidemiology |
---|---|
2 | Molecular biology |
3 | Pathology |
4 | Genomics |
5 | Translational research |
6 | Biomarker |
7 | Tumor microenvironment |
8 | AI |
9 | Endoscopic therapy |
10 | Endoscopic diagnosis |
11 | Imaging diagnosis |
12 | H.pylori |
13 | Progression of gastric cancer |
14 | Rare metastasis / Micrometastasis |
15 | Intraoperative frozen section |
16 | Cancer stem cell |
17 | Clinical pathology |
18 | Prognostic factor |
19 | Precision medicine |
20 | Clinical study |
21 | Chemotherapy |
22 | Neoadjuvant chemotherapy |
23 | Adjuvant chemotherapy |
24 | Second-line chemotherapy |
25 | Third-line chemotherapy |
26 | Intraperitoneal chemotherapy |
27 | Molecular targeted therapy |
28 | Immunotherapy |
29 | Radiation therapy |
30 | conversion surgery |
31 | Surgery |
32 | Laparoscopic surgery |
33 | Robot surgery |
34 | Function-preserving surgery |
35 | Cytoreductive surgery |
36 | LECS |
37 | Surgical navigation |
38 | Postoperative functional assessment |
39 | Postgastrectomy syndrome |
40 | Perioperative management |
41 | Postoperative complications |
42 | ERAS |
---|---|
43 | Navigation Surgery |
44 | Peritoneal dissemination |
45 | CART |
46 | Stent placement |
47 | Liver metastasis |
48 | Recurrence |
49 | Early gastric cancer |
50 | Advanced gastric cancer |
51 | Scirrhous gastric cancer |
52 | Gastric stump carcinoma |
53 | Multiple gastric cancers |
54 | Gastric tube cancer |
55 | Esophago-gastric junction cancer |
56 | Gastric cancer in elderly patients |
57 | AFP-producing gastric cancer |
58 | EBV-related gastric cancer |
59 | Gastrointestinal stromal tumor |
60 | Malignant lymphoma |
61 | Gastric neuroendocrine tumor |
62 | Guidelines |
63 | Clinical pathway |
64 | Postoperative surveillance |
65 | Long-term survival case after chemotherapy |
66 | NST |
67 | Outcome |
68 | QOL assessment |
69 | Cachexia |
70 | Nutrition |
71 | Obesity |
72 | Case report |
73 | Japanese Classification of Gastric Carcinoma |
74 | Multidisciplinary treatment |
75 | Palliative therapy |
76 | Team approach |
77 | Patient Advocacy |
78 | MDT conference |
79 | Medical cooperation |
80 | Oral care |
81 | EFTR |
82 | Others |
Abstract Acceptance or Rejection
Please note that the decision on abstract acceptance/rejection is left to the sole discretion of the Congress President.
Abstract Submission
Language for abstract
English
Language for presentation
English
Language for presentation slides
English
The number of characters
Title: up to 100 characters (including spaces)
Abstract: up to 1600 characters (including spaces)
Conflict of Interest Disclosure
The author is required to report applicable COI (Conflict of Interest) by completing the "Conflict of Interest Disclosure" part in the Abstract Submission process.
Abstract Submission
Inquiries
Secretariat of 95th Annual Meeting of The Japanese Gastric Cancer Association
c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2, Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
E-mail: endai-95jgca@convention.co.jp